Paradigm Biocapital Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$142M	Buy	+3,574,048	New	+$91.4M	2.9%	11

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Paradigm Biocapital Advisors's CNTA Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 3,574,048 shares worth $142M. The stake represents 2.9% of the portfolio and ranks #11 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Paradigm Biocapital Advisors held 3,574,048 shares of Centessa Pharmaceuticals worth $142M as of Q1 2026.
Centessa Pharmaceuticals was a new Paradigm Biocapital Advisors position in Q1 2026.
Centessa Pharmaceuticals made up 2.9% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #11 holding.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.